ScreenerHero

ZYMEZymeworks Inc.

NYSE · US · Healthcare · Biotechnology · zymeworks.com
28.67USDMkt Cap: 2.05B $P/E: —

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjug…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap2.05B $
Enterprise Value1.78B $
Revenue (TTM)37.13M $
Gross Profit-91.58M $
Net Income (TTM)-81.13M $
Revenue/Share0.4970 USD
Last Price28.67 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees231
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS98985Y1082
Valuation
P/E (Trailing)—
P/E (Forward)24.36
PEG—
EV/EBITDA-11.81
EV/Revenue47.94
P/S55.22
P/B13.08
EPS (TTM)-2.02
EPS (Forward)1.18
52W Range
26.7796% of range28.74
52W High28.74 USD
52W Low26.77 USD
Profitability
Gross Margin-246.66%
Oper. Margin-918.95%
EBITDA Margin0.00%
Profit Margin-76.56%
ROE-30.22%
ROA-23.41%
Growth
Revenue Growth-90.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-33.01M $
CapEx (TTM)2.35M $
FCF Margin-175.24%
FCF Yield-3.17%
Net Debt-254.69M $
Net Debt/EBITDA1.69
Balance Sheet
Debt/Equity0.07
Current Ratio6.32
Quick Ratio5.86
Book Value/Sh2.192 USD
Cash/Share3.815 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)40.33 USD
Upside (mean)+40.7%
Target Range31.00 USD – 58.00 USD
$31.00+40.7% to mean$58.00
# Analysts12
Ownership
Shares Out.70.96M
Float65.84M
Insiders1.31%
Institutions98.76%
Short Interest
Short Ratio8.4d
Short % Float8.62%
Short % Out.5.75%
Shares Short4.11M
Short (prev mo.)4.36M
Technical
SMA 5024.32 (+17.9%)
SMA 20024.46 (+17.2%)
Beta1.15
S&P 52W Chg19.18%
Avg Vol (30d)834.37K
Avg Vol (10d)611.41K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—